ZYMEWORKS INC. - COMMON STOCK

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

30 مايو 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

22 مايو 2025 14:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 مايو 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

19 مايو 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

08 مايو 2025 13:04:03 بحسب Nasdaq GlobeNewswire

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

25 أبريل 2025 10:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

21 أبريل 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

17 أبريل 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

26 مارس 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

25 مارس 2025 13:30:35 بحسب Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

05 مارس 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

26 فبراير 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

25 فبراير 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

18 فبراير 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

13 فبراير 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 يناير 2025 03:00:00 بحسب Nasdaq GlobeNewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

08 يناير 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

12 ديسمبر 2024 05:30:00 بحسب Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

21 نوفمبر 2024 03:05:00 بحسب Nasdaq GlobeNewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

21 نوفمبر 2024 03:00:00 بحسب Nasdaq GlobeNewswire